Tenofovir versus placebo to prevent perinatal transmission of hepatitis B

New England Journal of Medicine

Volumn 378, Issue 10, 2018, Pages 911-923

  Jourdain, G ^a,b,w   Ngo Giang Huong, N ^a,b,w   Harrison, L ^x   Decker, L ^a,b   Khamduang, W ^b   Tierney, C ^x   Salvadori, N ^a,b   Cressey, T R ^a,b,z   Sirirungsi, W ^b   Achalapong, J ^b,c   Yuthavisuthi, P ^h   Kanjanavikai, P ⁱ   Na Ayudhaya, O P ^k   Siriwachirachai, T ⁿ   Prommas, S ^l   Sabsanong, P ^o   Limtrakul, A ^c   Varadisai, S ^p   Putiyanun, C ^q   Suriyachai, P ^r   Liampongsabuddhi, P ^s   Sangsawang, S ^d   Matanasarawut, W ^t   Buranabanjasatean, S ^g   Puernngooluerm, P ^u   Bowonwatanuwong, C ^j   Puthanakit, T ^m   Klinbuayaem, V ^e   Thongsawat, S ^f   Thanprasertsuk, S ^n,v   Siberry, G K ^aa   Watts, D H ^ab   Chakhtoura, N ^aa   Murphy, T V ^ac   Nelson, N P ^ac   Chung, R T ^w,y   Pol, S ^ad   Chotivanich, N ^j   more..

^a Institute of research for development Thailand   (Thailand)

^b CHIANG MAI UNIVERSITY   (Thailand)

^c NAKORNPING HOSPITAL   (Thailand)

^d Health Promotion Center Region 1   (Thailand)

^e Sanpatong Hospital   (Thailand)

^f THAMMASAT UNIVERSITY   (Thailand)

^g Mae Chan Hospital   (Thailand)

^h PRAPOKKLAO HOSPITAL   (Thailand)

ⁱ Banglamung Hospital   (Thailand)

^j CHONBURI HOSPITAL   (Thailand)

^k Nopparat Rajathanee Hospital   (Thailand)

^l BHUMIBOL ADULYADEJ HOSPITAL   (Thailand)

^m CHULALONGKORN UNIVERSITY   (Thailand)

ⁿ KHON KAEN HOSPITAL   (Thailand)

^o Samutprakarn Hospital   (Thailand)

^p Samutsakhon General Hospital   (Thailand)

^q Chiang Kham Hospital   (Thailand)

^r Phayao Hospital   (Thailand)

^s LAMPANG HOSPITAL   (Thailand)

^t Lamphun Hospital   (Thailand)

^u Maharaj Nakornratchasrima Hospital   (Thailand)

^v MINISTRY OF PUBLIC HEALTH   (Thailand)

^w Ministry of Public Health ^*  (United States)

^x CENTER FOR BIOSTATISTICS IN AIDS RESEARCH   (United States)

^y MASSACHUSETTS GENERAL HOSPITAL   (United States)

^z UNIVERSITY OF LIVERPOOL   (United Kingdom)

^aa EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^ab U S DEPARTMENT OF STATE   (United States)

^ac CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^ad UNIVERSITÉ PARIS DESCARTES   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; HEPATITIS B ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; HEPATITIS B(E) ANTIGEN; PLACEBO; TENOFOVIR DISOPROXIL; VIRUS DNA; ANTIVIRUS AGENT; TENOFOVIR;

ADULT; ALANINE AMINOTRANSFERASE LEVEL; ANTIGEN DETECTION; ARTICLE; CHILDBIRTH; CONTROLLED STUDY; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG WITHDRAWAL; FEMALE; GESTATION PERIOD; GESTATIONAL AGE; HEPATITIS B; HUMAN; HYPERBILIRUBINEMIA; INFANT; INFECTION PREVENTION; JAUNDICE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PARALLEL DESIGN; PHASE 3 CLINICAL TRIAL; PREGNANT WOMAN; PRIORITY JOURNAL; PUERPERIUM; SIDE EFFECT; STILLBIRTH; THAILAND; TWIN PREGNANCY; VERTICAL TRANSMISSION; VIRUS TRANSMISSION; ADOLESCENT; BLOOD; CLINICAL TRIAL; GENETICS; HEPATITIS B VIRUS; ISOLATION AND PURIFICATION; NEWBORN; PREGNANCY; PREGNANCY COMPLICATION; PREVENTION AND CONTROL; RANDOMIZED CONTROLLED TRIAL; TRANSMISSION; VIRUS LOAD; YOUNG ADULT;

ADOLESCENT; ADULT; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; DNA, VIRAL; DOUBLE-BLIND METHOD; FEMALE; HEPATITIS B; HEPATITIS B E ANTIGENS; HEPATITIS B VACCINES; HEPATITIS B VIRUS; HUMANS; INFANT; INFANT, NEWBORN; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; MALE; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; TENOFOVIR; VIRAL LOAD; YOUNG ADULT;

EID: 85043605260     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1708131     Document Type: Article

References (32)

1. Beasley RP. Hepatitis B virus: the major etiology of hepatocellular carcinoma. Cancer 1988; 61: 1942-56.
2. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004; 11: 97-107.
3. World Health Organization. Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection. March 2015 (http://apps .who .int/ iris/ bitstream/ 10665/ 154590/ 1/ 9789241549059 -eng .pdf).
4. Margolis HS, Coleman PJ, Brown RE, Mast EE, Sheingold SH, Arevalo JA. Prevention of hepatitis B virus transmission by immunization: an economic analysis of current recommendations. JAMA 1995; 274: 1201-8.
5. Stevens CE, Beasley RP, Tsui J, Lee W-C. Vertical transmission of hepatitis B antigen in Taiwan. N Engl J Med 1975; 292: 771-4.
6. Chan C-Y, Lee S-D, Lo K-J. Legend of hepatitis B vaccination: the Taiwan experience. J Gastroenterol Hepatol 2004; 19: 121-6.
7. Posuwan N, Wanlapakorn N, Sa- Nguanmoo P, et al. The success of a universal hepatitis B immunization program as part of Thailand's EPI after 22 years' implementation. PLoS One 2016; 11(3): e0150499.
8. Lee C, Gong Y, Brok J, Boxall EH, Gluud C. Effect of hepatitis B immunisation in newborn infants of mothers positive for hepatitis B surface antigen: systematic review and meta-analysis. BMJ 2006; 332: 328-36.
9. Xu W-M, Cui Y-T, Wang L, et al. Lamivudine in late pregnancy to prevent perinatal transmission of hepatitis B virus infection: a multicentre, randomized, double-blind, placebo-controlled study. J Viral Hepat 2009; 16: 94-103.
10. Han G-R, Cao M-K, Zhao W, et al. A prospective and open-label study for the efficacy and safety of telbivudine in pregnancy for the prevention of perinatal transmission of hepatitis B virus infection. J Hepatol 2011; 55: 1215-21.
11. Chen H-L, Lee C-N, Chang C-H, et al. Efficacy of maternal tenofovir disoproxil fumarate in interrupting mother-to-infant transmission of hepatitis B virus. Hepatology 2015; 62: 375-86.
12. Terrault NA, Bzowej NH, Chang K-M, Hwang JP, Jonas MM, Murad MH. AASLD guidelines for treatment of chronic hepatitis B. Hepatology 2016; 63: 261-83.
13. Pan CQ, Duan Z, Dai E, et al. Tenofovir to prevent hepatitis B transmission in mothers with high viral load. N Engl J Med 2016; 374: 2324-34.
14. Wen W-H, Chang M-H, Zhao L-L, et al. Mother-to-infant transmission of hepatitis B virus infection: significance of maternal viral load and strategies for intervention. J Hepatol 2013; 59: 24-30.
15. Oon CJ, Chen WN. Current aspects of hepatitis B surface antigen mutants in Singapore. J Viral Hepat 1998; 5: Suppl 2: 17-23.
16. Carman WF, Zanetti AR, Karayiannis P, et al. Vaccine-induced escape mutant of hepatitis B virus. Lancet 1990; 336: 325-9.
17. Blanche S, Tardieu M, Benhammou V, Warszawski J, Rustin P. Mitochondrial dysfunction following perinatal exposure to nucleoside analogues. AIDS 2006; 20: 1685-90.
18. World Health Organization. Hepatitis B and breastfeeding. November 1996 (http:// www .who .int/ maternal-child-adolescent/ documents/ pdfs/ hepatitis-b-and -breastfeeding .pdf).
19. Jourdain G, Ngo-Giang-Huong N, Cressey TR, et al. Prevention of motherto- child transmission of hepatitis B virus: a phase III, placebo-controlled, doubleblind, randomized clinical trial to assess the efficacy and safety of a short course of tenofovir disoproxil fumarate in women with hepatitis B virus e-antigen. BMC Infect Dis 2016; 16: 393.
20. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH harmonised tripartite guideline: guideline for Good Clinical Practice E6(R1): current Step 4 version. June 10, 1996 (https://www.ich.org/fileadmin/Public -Web-Site/ICH-Products/Guidelines/ Efficacy/E6/E6-R1-Guideline.pdf).
21. Division of AIDS table for grading the severity of adult and pediatric adverse events. 2004 (http://rsc .tech-res .com/ docs/ default-source/ safety/ table-for-grading -severity-of-adult-pediatric-adverse -events .pdf?sfvrsn=6).
22. Brown EG, Wood L, Wood S. The Medical Dictionary for Regulatory Activities (MedDRA). Drug Saf 1999; 20: 109-17.
23. Hanley JA, Lippman-Hand A. If nothing goes wrong, is everything all right? Interpreting zero numerators. JAMA 1983; 249: 1743-5.
24. Chen HL, Lin LH, Hu FC, et al. Effects of maternal screening and universal immunization to prevent mother-to-infant transmission of HBV. Gastroenterology 2012; 142(4): 773-781.e2.
25. Szmuness W, Stevens CE, Harley EJ, et al. Hepatitis B vaccine: demonstration of efficacy in a controlled clinical trial in a high-risk population in the United States. N Engl J Med 1980; 303: 833-41.
26. Iwarson S, Wahl M, Ruttimann E, Snoy P, Seto B, Gerety RJ. Successful postexposure vaccination against hepatitis B in chimpanzees. J Med Virol 1988; 25: 433-9.
27. Wahl M, Iwarson S, Snoy P, Gerety RJ. Failure of hepatitis B immune globulin to protect against exp infection in chimpanzees. J Hepatol 1989; 9: 198-203.
28. Expert Committee. Thailand practice guidelines for management of chronic hepatitis B and C, 2012. Bangkok, Thailand: Thai Association for the Study of the Liver, 2012. (In Thai.)
29. Pan CQ, Zou H-B, Chen Y, et al. Cesarean section reduces perinatal transmission of hepatitis B virus infection from hepatitis B surface antigen-positive women to their infants. Clin Gastroenterol Hepatol 2013; 11: 1349-55.
30. Bian T, Yan H, Shen L, et al. Change in hepatitis B virus large surface antigen variant prevalence 13 years after implementation of a universal vaccination program in China. J Virol 2013; 87: 12196-206.
31. Fowler MG, Qin M, Fiscus SA, et al. Benefits and risks of antiretroviral therapy for perinatal HIV prevention. N Engl J Med 2016; 375: 1726-37.
32. Sarin SK, Kumar M, Lau GK, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int 2016; 10: 1-98.